Predicting benefit from anti-angiogenic agents in malignancy
AM Jubb, AJ Oates, S Holden, H Koeppen - Nature Reviews Cancer, 2006 - nature.com
AM Jubb, AJ Oates, S Holden, H Koeppen
Nature Reviews Cancer, 2006•nature.comA high probability of benefit is desirable to justify the choice of anti-angiogenic therapy from
an ever-expanding list of expensive new anticancer agents. However, biomarkers of
response to cytotoxic agents are not optimal for predicting benefit from anti-angiogenic
drugs. This discussion will focus on both preclinical and clinical research to identify
biomarkers for anti-angiogenic therapies that can inform dosing, early clinical benefit, initial
drug choice, emerging resistance and second-line treatments.
an ever-expanding list of expensive new anticancer agents. However, biomarkers of
response to cytotoxic agents are not optimal for predicting benefit from anti-angiogenic
drugs. This discussion will focus on both preclinical and clinical research to identify
biomarkers for anti-angiogenic therapies that can inform dosing, early clinical benefit, initial
drug choice, emerging resistance and second-line treatments.
Abstract
A high probability of benefit is desirable to justify the choice of anti-angiogenic therapy from an ever-expanding list of expensive new anticancer agents. However, biomarkers of response to cytotoxic agents are not optimal for predicting benefit from anti-angiogenic drugs. This discussion will focus on both preclinical and clinical research to identify biomarkers for anti-angiogenic therapies that can inform dosing, early clinical benefit, initial drug choice, emerging resistance and second-line treatments.
nature.com